.jpg?format=webp&width=780)
Ranitidine, withdrawn in 2020 over cancer concerns, has received a clean bill of health. A study found no elevated cancer risk with ranitidine compared to other H2RAs. Analyzing data from multiple countries, including the US and UK, the research covered 1,183,999 individuals. After rigorous analysis, no statistically significant cancer risk difference emerged. The calibrated hazard ratio was 1.04 (95% confidence interval: 0.97–1.12), indicating no increased cancer risk with ranitidine.
Like
Save
Share